Skip to main content
Premium Trial:

Request an Annual Quote

Valted Seq Raises $10.5M Seed Funding

NEW YORK – Neurodegenerative disease diagnostics firm Valted Seq said on Tuesday that it has raised a seed financing round of $10.5 million.

Dongkoo Bio&Pharma led the round, joined by new investor OV Principal Investments and several independent investors.

Valted Seq has been developing a platform called HiF-Seq for collecting single-cell sequencing data from postmortem brains of patients with neurodegenerative diseases such as Parkinson's and Alzheimer's. It plans to partner with biopharmaceutical firms to apply the platform.

"This financing will accelerate the development of our HiF-Seq platform, generating the largest single-nucleus sequence database for Parkinson's disease," Valted Seq interim CEO Nina Urban said in a statement. "Interrogating the transcriptomic fingerprints of this highly complex and poorly understood disease will lead to validated drug targets and biomarkers."

The Gaithersburg, Maryland-based firm has raised at least $17 million in total, with $7 million in pre-seed funding from South Korea-based parent company D&D Pharmatech. It has obtained exclusive rights to evaluate biomarker assays developed at Johns Hopkins University that could be used to diagnose and manage neurodegenerative diseases.

Besides HiF-Seq, the firm is developing minimally invasive assays for detecting poly (ADP-ribose) in cerebral spinal fluid, serum, and serum-derived exosomes for diagnosis of Parkinson's disease, and for assessing c-Abl pathway molecules from the same sample types for diagnosing Parkinson's and related alpha-synucleinopathies.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.